Penetration Efficiency of Antitumor Agents in Ovarian Cancer Spheroids: The Case of Recombinant Targeted Toxin DARPin-LoPE and the Chemotherapy Drug, Doxorubicin; Pharmaceutics; Vol. 11, iss. 5
| Parent link: | Pharmaceutics Vol. 11, iss. 5.— 2019.— [219, 16 p.] |
|---|---|
| Autor kompanije: | |
| Daljnji autori: | , , , , , , , |
| Sažetak: | Title screen The efficiency of delivering a therapeutic agent into a tumor is among the crucial factors determining the prospects for its clinical use. This problem is particularly acute in the case of targeted antitumor agents since many of them are high-molecular-weight compounds. In this work, the penetration of therapeutic agents of two distinct molecular weights into the spheroids of ovarian adenocarcinoma overexpressing human epidermal growth factor receptor 2 (HER2) was studied. It was shown that the low-molecular-weight chemotherapy drug, doxorubicin (~0.5 kDa), effectively penetrates through almost the entire depth of a 300 to 400 µm spheroid, while the penetration depth of the HER2-specific recombinant targeted toxin, DARPin-LoPE (~42 kDa), is only a few surface layers of cells and does not exceed 70 µm. The low penetration of the targeted toxin into spheroid was shown along with a significant decrease in its efficiency against the three-dimensional tumor spheroid as compared with the two-dimensional monolayer culture. The approaches to increasing the accumulation of agents in the tumor are presented and prospects of their use in order to improve the effectiveness of therapy are discussed. |
| Jezik: | engleski |
| Izdano: |
2019
|
| Teme: | |
| Online pristup: | https://doi.org/10.3390/pharmaceutics11050219 |
| Format: | Elektronički Poglavlje knjige |
| KOHA link: | https://koha.lib.tpu.ru/cgi-bin/koha/opac-detail.pl?biblionumber=664212 |
MARC
| LEADER | 00000naa0a2200000 4500 | ||
|---|---|---|---|
| 001 | 664212 | ||
| 005 | 20260506155745.0 | ||
| 035 | |a (RuTPU)RU\TPU\network\35396 | ||
| 035 | |a RU\TPU\network\27249 | ||
| 090 | |a 664212 | ||
| 100 | |a 20210331d2019 k||y0rusy50 ba | ||
| 101 | 0 | |a eng | |
| 135 | |a drcn ---uucaa | ||
| 181 | 0 | |a i | |
| 182 | 0 | |a b | |
| 200 | 1 | |a Penetration Efficiency of Antitumor Agents in Ovarian Cancer Spheroids: The Case of Recombinant Targeted Toxin DARPin-LoPE and the Chemotherapy Drug, Doxorubicin |f E. A. Sokolova, O. M. Kutova, A. I. Grishina [et al.] | |
| 203 | |a Text |c electronic | ||
| 300 | |a Title screen | ||
| 320 | |a [References: 51 tit.] | ||
| 330 | |a The efficiency of delivering a therapeutic agent into a tumor is among the crucial factors determining the prospects for its clinical use. This problem is particularly acute in the case of targeted antitumor agents since many of them are high-molecular-weight compounds. In this work, the penetration of therapeutic agents of two distinct molecular weights into the spheroids of ovarian adenocarcinoma overexpressing human epidermal growth factor receptor 2 (HER2) was studied. It was shown that the low-molecular-weight chemotherapy drug, doxorubicin (~0.5 kDa), effectively penetrates through almost the entire depth of a 300 to 400 µm spheroid, while the penetration depth of the HER2-specific recombinant targeted toxin, DARPin-LoPE (~42 kDa), is only a few surface layers of cells and does not exceed 70 µm. The low penetration of the targeted toxin into spheroid was shown along with a significant decrease in its efficiency against the three-dimensional tumor spheroid as compared with the two-dimensional monolayer culture. The approaches to increasing the accumulation of agents in the tumor are presented and prospects of their use in order to improve the effectiveness of therapy are discussed. | ||
| 461 | |t Pharmaceutics | ||
| 463 | |t Vol. 11, iss. 5 |v [219, 16 p.] |d 2019 | ||
| 610 | 1 | |a электронный ресурс | |
| 610 | 1 | |a труды учёных ТПУ | |
| 610 | 1 | |a drug penetration into tumor | |
| 610 | 1 | |a HER2 | |
| 610 | 1 | |a spheroid | |
| 610 | 1 | |a targeted therapy | |
| 610 | 1 | |a targeted toxin | |
| 610 | 1 | |a DARPin | |
| 610 | 1 | |a Pseudomonas exotoxin A | |
| 610 | 1 | |a лекарства | |
| 610 | 1 | |a опухоли | |
| 610 | 1 | |a сфероид | |
| 701 | 1 | |a Sokolova |b E. A. |g Evgeniya Aleksandrovna | |
| 701 | 1 | |a Kutova |b O. M. |g Olga Mikhaylovna | |
| 701 | 1 | |a Grishina |b A. I. |g Alena Igorevna | |
| 701 | 1 | |a Pospelov |b A. Dz. |g Anton Dzhonovich | |
| 701 | 1 | |a Gurjev |b E. L. |g Evgeny Leonidovich | |
| 701 | 1 | |a Shulga |b A. A. |c biologist |c Researcher, Tomsk Polytechnic University, Candidate of Biological Sciences |f 1960- |g Aleksey Anatolievich |3 (RuTPU)RU\TPU\pers\46796 | |
| 701 | 1 | |a Deev |b S. M. |c biologist |c Leading Researcher, Tomsk Polytechnic University, Doctor of Biological Sciences |f 1951- |g Sergey Mikhaylovich |3 (RuTPU)RU\TPU\pers\39299 |9 20959 | |
| 701 | 1 | |a Balalaeva |b I. V. |g Irina Vladimirovna | |
| 712 | 0 | 2 | |a Национальный исследовательский Томский политехнический университет |b Физико-технический институт |b Лаборатория № 31 ядерного реактора |3 (RuTPU)RU\TPU\col\20054 |
| 801 | 0 | |a RU |b 63413507 |c 20210331 |g RCR | |
| 850 | |a 63413507 | ||
| 856 | 4 | |u https://doi.org/10.3390/pharmaceutics11050219 | |
| 942 | |c CF | ||